The increase was mainly on account of recognition of income from settlement agreement, with Indivior Inc, Indivior UK Limited and Aquestive Therapeutics, Inc, on its generic version of opioid addiction treatment drug Suboxone, Chief Financial officer Dr Reddy's Parag Agarwal said. "Basically the results are impacted in a positive way by two things which is Suboxone settlement which is another operating income and also the brand divestments. Brand divestments have recorded in sales and growth margin. These are the two major upsides that are benefitting," Agarwal said. He further said the company has received USD 50 million out of the total USD 72 million towards Suboxone settlement. DR Reddy's CEO Erez Israeli the company is working on its COVID-19 vaccine Sputnik Light as a universal booster dose. "We are in the last stages of finalizing the trial in India to qualify Sputnik as a booster for other vaccines in India.